This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Marc A. Pfeffer, MD, PhD; Lemuel A. Moyé, MD, PhD; Eugene Braunwald, MD; Lofty Basta, MD; Edward J. Brown, Jr, MD; Thomas E. Cuddy, MD; Gilles R. Dagenais, MD; Gregory C. Flaker, MD; Edward M. Geltman, MD; Bernard J. Gersh, MD; Steven Goldman, MD; Gervasio A. Lamas, MD; Milton Packer, MD; Jean L. Rouleau, MD; John D. Rutherford, MD; Richard M. Steingart, MD; John H. Wertheimer, MD

JAMA. 1991;266(4):528-532.

Abstract
Objective.
—To determine whether clinical selection for thrombolytic therapy for acute myocardial infarction results in a skewed population for subsequent adverse cardiovascular events.

Design.
—A comparison of the clinical features of the patients in the Survival and Ventricular Enlargement Study who either had or had not received thrombolytic therapy was conducted in both univariate and multiple logistic regression analyses.

Setting.
—Hospitalized patients experiencing acute myocardial infarction from 112 broadly representative, private, academic, and government hospitals in the United States and Canada.

Patients.
—All patients in the Survival and Ventricular Enlargement Study had had a recent myocardial infarction (<16 days) and had a left ventricular ejection fraction of 40% or less.

Intervention.
—Thrombolytic therapy was administered to 733 patients and was not given to 1498.

Main Outcome Measures.
—The comparisons with respect to use of thrombolytic therapy were formulated after the completion of enrollment and indicated that the majority of patients did not receive thrombolytic therapy.

Results.
—The 1498 (67.1%) patients who did not receive thrombolytic therapy were at higher risk (older age, lower functional capacity, greater likelihood of a history of prior myocardial infarction, angina, diabetes, and hypertension) for subsequent cardiovascular events and, as anticipated, were more likely to have concomitant gastrointestinal and neurological diseases. A multiple logistic regression analysis indicated that older age, prior myocardial infarction, impaired functional status, employment status, diabetes, and neurological diseases were predictors of use of thrombolytic therapy.

Conclusion.
—Although the Survival and Ventricular Enlargement Study population was selected for left ventricular dysfunction, the majority of patients who currently are judged clinically as unsuitable for thrombolytic therapy have a higher risk for adverse cardiovascular events.

(JAMA. 1991;266:528-532)

Author Affiliations
From the Harvard Medical School, Brigham and Women's Hospital, Boston, Mass (Drs Pfeffer, Braunwald, Lamas, and Rutherford); University of Texas, Health Science Center at Houston (Dr Moyé); Tulsa (Okla) Heart Center (Dr Basta); the State University of New York, Stony Brook (Dr Brown); University of Manitoba, Winnipeg (Dr Cuddy); Institut de Cardiologie de Quebec, Ste-Foy (Dr Dagenais); University of Missouri, Columbia (Dr Flaker); Washington University School of Medicine, St Louis, Mo (Dr Geltman); Mayo Clinic, Rochester, Minn (Dr Gersh); Tucson (Ariz) Veterans Administration Medical Center (Dr Goldman); Mount Sinai Medical Center, New York, NY (Dr Packer); Hôpital du Sacré-Coeur, Montreal, Quebec (Dr Rouleau); Winthrop University Hospital, Mineola, NY (Dr Steingart); and Albert Einstein Medical Center, Philadelphia, Pa (Dr Wertheimer). Dr Rouleau is now with the University de Sherbrooke, Quebec

Footnotes
Reprint requests to Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115 (Dr Pfeffer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Heart failure complicating acute myocardial infarction in patients with diabetes: pathophysiology and management strategies
Sulfi and Timmis
British Journal of Diabetes & Vascular Disease 2006;6:191-196.
ABSTRACT  

The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes
Collet and Montalescot
Diabetes and Vascular Disease Research 2005;2:136-143.
ABSTRACT  

Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Aguilar et al.
Circulation 2004;110:1572-1578.
ABSTRACT | FULL TEXT  

Acute coronary syndromes and diabetes mellitus
Trichon and Roe
Diabetes and Vascular Disease Research 2004;1:23-32.
ABSTRACT  

Gender differences in advanced heart failure: insights from the BEST study
Ghali et al.
J Am Coll Cardiol 2003;42:2128-2134.
ABSTRACT | FULL TEXT  

Review: The management of acute myocardial infarction in patients with diabetes mellitus
Williams et al.
British Journal of Diabetes & Vascular Disease 2003;3:319-324.
ABSTRACT  

Consequences of overutilization and underutilization of thrombolytic therapy in clinical practice
Ottesen et al.
J Am Coll Cardiol 2001;37:1581-1587.
ABSTRACT | FULL TEXT  

Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction
Boucher et al.
CMAJ 2001;164:1285-1290.
ABSTRACT | FULL TEXT  

Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry
Shindler et al.
J Am Coll Cardiol 2000;36:1097-1103.
ABSTRACT | FULL TEXT  

Management of coronary artery disease: therapeutic options in patients with diabetes
Hammoud et al.
J Am Coll Cardiol 2000;36:355-365.
ABSTRACT | FULL TEXT  

Lack of Benefit for Intravenous Thrombolysis in Patients With Myocardial Infarction Who Are Older Than 75 Years
Thiemann et al.
Circulation 2000;101:2239-2246.
ABSTRACT | FULL TEXT  

The Treatment of Elderly Diabetic Patients With Acute Myocardial Infarction: Insight From Michigan's Cooperative Cardiovascular Project
Mehta et al.
Arch Intern Med 2000;160:1301-1306.
ABSTRACT | FULL TEXT  

Reducing Time Delay in the Thrombolysis of Myocardial Infarction: An Internal Quality Improvement Project
Saturno et al.
American Journal of Medical Quality 2000;15:85-93.
ABSTRACT  

Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus
Mak and Topol
J Am Coll Cardiol 2000;35:563-568.
ABSTRACT | FULL TEXT  

Long-term (three-year) prognosis of patients treated with reperfusion or conservatively after acute myocardial infarction
Gottlieb et al.
J Am Coll Cardiol 1999;34:70-82.
ABSTRACT | FULL TEXT  

Treatment and Outcome of Patients With Acute Myocardial Infarction and Prior Cerebrovascular Events in the Thrombolytic Era: The Israeli Thrombolytic National Survey
Tanne et al.
Arch Intern Med 1998;158:601-606.
ABSTRACT | FULL TEXT  

Thrombolytic Therapy for Eligible Elderly Patients With Acute Myocardial Infarction
Krumholz et al.
JAMA 1997;277:1683-1688.
ABSTRACT  

Improved Outcome of Elderly Patients (>=75 Years of Age) With Acute Myocardial Infarction From 1981-1983 to 1992-1994 in Israel
Gottlieb et al.
Circulation 1997;95:342-350.
ABSTRACT | FULL TEXT  

Infarct Size After Acute Myocardial Infarction Measured by Quantitative Tomographic 99mTc Sestamibi Imaging Predicts Subsequent Mortality
Miller et al.
Circulation 1995;92:334-341.
ABSTRACT | FULL TEXT  

Thrombolysis in patients with diabetes
Ward and Yudkin
BMJ 1995;310:3-4.
FULL TEXT  

Improved Health Benefits of Increased Use of Thrombolytic Therapy
Fendrick et al.
Arch Intern Med 1994;154:1605-1609.
ABSTRACT  

Variation in Practice for Discretionary Admissions: Impact on Estimates of Quality of Hospital Care
Miller et al.
JAMA 1994;271:1493-1498.
ABSTRACT  

The Benefits of Aspirin in Acute Myocardial Infarction: Still a Well-Kept Secret in the United States
Hennekens et al.
Arch Intern Med 1994;154:37-40.
ABSTRACT  

Thrombolytic Therapy of Acute Myocardial Infarction: Keeping the Unfulfilled Promises
Doorey et al.
JAMA 1992;268:3108-3114.
ABSTRACT  

HIGH-RISK PATIENTS ARE OFTEN EXCLUDED FROM THROMBOLYTIC THERAPY
JWatch General 1991;1991:3-3.
FULL TEXT